Terms: = Thyroid cancer AND CEACAM5, CEA AND Clinical Outcome
4 results:
1. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract] [Full Text] [Related]
2. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
[TBL] [Abstract] [Full Text] [Related]
3. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?
Bümming P; Ahlman H; Nilsson B; Nilsson O; Wängberg B; Jansson S
Langenbecks Arch Surg; 2008 Sep; 393(5):699-703. PubMed ID: 18626656
[TBL] [Abstract] [Full Text] [Related]
4. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Stein R; Goldenberg DM
Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
[TBL] [Abstract] [Full Text] [Related]